Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Rituximab MeSH Descriptor Data 2025


MeSH Heading
Rituximab
Tree Number(s)
D12.776.124.486.485.114.224.075.785
D12.776.124.790.651.114.224.075.785
D12.776.377.715.548.114.224.284.785
Unique ID
D000069283
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000069283
Scope Note
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
Entry Term(s)
CD20 Antibody, Rituximab
GP2013
IDEC-C2B8
IDEC-C2B8 Antibody
Mabthera
Rituxan
Pharm Action
Immunologic Factors
Antirheumatic Agents
Antineoplastic Agents, Immunological
Registry Numbers
4F4X42SYQ6
0
Related Numbers
174722-31-7
See Also
Antigens, CD20
Public MeSH Note
2016; RITUXIMAB was indexed under ANTIBODIES, MONOCLONAL, MURINE-DERIVED 1995-2016
History Note
2016 (1995)
Date Established
2016/01/01
Date of Entry
2015/07/01
Revision Date
2020/05/27
Rituximab Preferred
Rituxan Narrower
IDEC-C2B8 Antibody Narrower
Mabthera Narrower
GP2013 Narrower
page delivered in 0.13s